JPRN-jRCTs031210087进行中（未招募）2 期
A Placebo-Controlled, Randomized, Double-Blind, Parallel-Group Study of the Efficacy of 1-Kestose on the Intestinal Environment of Pregnant Women.
Ide Yoshihiro0 个研究点目标入组 70 人开始时间: 2021年5月13日最近更新:
试验速览
- 阶段
- 2 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 70
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 <= 39age old（—）
- 性别
- Female
入选标准
- •1) Healthy pregnant women who are between 20 and 40 years of age at the time of consent.
- •2) Patients who have received sufficient explanation about the study, can understand the contents, and can give written consent in person.
排除标准
- •1) Patients on medication
- •2) Those with gestational diabetes or high blood pressure in pregnancy
- •3) Those who have taken drugs (antibiotics) that affect the intestinal environment for one month prior to the start of the test food intake
- •4) Those who have a history of or are currently suffering from a serious disease of the heart, liver, kidneys, digestive organs, etc.
- •5) Heavy drinkers of alcohol
- •6) Smokers
- •7) Those with extremely irregular dietary habits, working hours, or rhythm of life
- •8) Those who are allergic to kestose or maltose
- •9) Those who are currently participating in a clinical trial of another drug or health food, or who plan to participate in another clinical trial within 4 weeks of completion of the trial, or after consenting to participate in the trial.
- •10) Those who are judged inappropriate to participate in the study by the principal investigator or sub-investigator.
研究者
相似试验
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Phase II study to Assess the efficacy of 28 Day Oral Administration of AZD1236 in Adult Patients with Cystic Fibrosis.Estudio fase II de distribución aleatoria, doble ciego, controlado con placebo y de grupos paralelos, para evaluar la eficacia de la administración oral durante 28 días de AZD1236 a pacientes adultos con fibrosis quística - CYBERCystic FibrosisFibrosis quísticaMedDRA version: 9.1Level: LLTClassification code 10011763Term: Cystic fibrosis lungEUCTR2008-004699-34-ESAstraZeneca AB50
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel-group, Multicentre, 24 week Study to Evaluate the Efficacy and Safety of Transdermal Testosterone (300 mcg/day) in Naturally Menopausal Women with Hypoactive Sexual Desire Disorder Receiving Systemic Transdermal Estrogen, Oral Non-Conjugated Equine Estrogen, or No Estrogen Therapy - ADOREHypoactive sexual desire disorderEUCTR2006-001179-39-DEProcter & Gamble Pharmaceuticals270
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-SEGlaxoSmithKline AB736
招募中
1 期
A study to learn if baxdrostat works at reducing blood pressure and is safe in people with high blood pressureCTIS2023-505499-32-00Astrazeneca AB720
进行中（未招募）
不适用
A Randomised, Double-Blind, Placebo-Controlled, Parallel Group, Multicentre, Long-Term Study to Evaluate the Safety of Once-Daily, Intranasal Administration of GW685698X Aqueous Nasal Spray 100mcg for 52 Weeks in Adult and Adolescent Subjects with Perennial Allergic RhinitisPerennial allergic rhinitisEUCTR2004-000091-14-LTGlaxoSmithKline736